Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 5/20 | 0.65 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.40 |
| ▸ | PTGES2 | Q9H7Z7 | 1/20 | 0.40 |
| ▸ | PSIP1 | O75475 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4984120 | 0.88 | GBA1 (0.59) | GBA1GRIA4MEN1KMT2AKCNA5 | |
| SCHEMBL4984422 | 0.85 | GBA1 (0.56) | GBA1GRIA4KCNA5MAPTHPGD | |
| SCHEMBL4985141 | 0.84 | GBA1 (0.67) | GBA1GRIA4 | |
| SCHEMBL4986251 | 0.79 | GBA1 (1.00) | GBA1MEN1KMT2ATP53MAPT | |
| SCHEMBL10216799 | 0.78 | PNMT (0.44) | GBA1MEN1KMT2ATP53MAPT | |
| SCHEMBL10217202 | 0.77 | ADRB2 (0.40) | GBA1GRIA4MEN1KMT2APSIP1 | |
| Hydrochloric Acid SCHEMBL3446039 | 0.77 | PNMT (0.43) | GBA1MEN1KMT2ATP53MAPT | |
| SCHEMBL4986451 | 0.76 | GBA1 (0.79) | GBA1MEN1KMT2ATP53MAPT | |
| Hydrochloric Acid SCHEMBL19244881 | 0.76 | BLM (0.40) | GBA1GRIA4MEN1KMT2APSIP1 | |
| SCHEMBL12879312 | 0.76 | GBA1 (0.79) | GBA1MEN1KMT2ATP53MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7393958-B2 | Triamide-substituted heterobicyclic compounds | PFIZER, INC. (US) | 2008-07-01 | — | — | US | disclosed |
| US-7368573-B2 | Triamide-substituted heterobicyclic compounds | PFIZER INC. (US) | 2008-05-06 | — | — | US | disclosed |
| US-20070093525-A1 | Triamide-substituted heterobicyclic compounds | PFIZER INC | 2007-04-26 | — | — | US | disclosed |
| US-20060223851-A1 | TRIAMIDE-SUBSTITUTED HETEROBICYCLIC COMPOUNDS | BERTINATO PETER | 2006-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060223851-A1 | TRIAMIDE-SUBSTITUTED HETEROBICYCLIC COMPOUNDS | APOB, MTPN, CTRB1 | GBA1 426/4885GRIA4 4068/4885MEN1 1637/4885 |
| US-20070093525-A1 | Triamide-substituted heterobicyclic compounds | APOB, MTPN, CTRB1 | GBA1 426/4885GRIA4 4068/4885MEN1 1637/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.